Uplizna (inebilizumab-cdon)

General Description

Uplizna (inebilizumab-cdon) is prescribed for adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-aquaporin-4 (AQP4) antibodies.

It is the first approved treatment for NMOSD that is administered just twice a year.

Getting Uplizna (inebilizumab-cdon) in India

Uplizna (inebilizumab-cdon) is approved in the U.S., Europe, and other countries, but it is not yet commercially available in India. However, eligible patients in India may access this important therapy through the Named Patient Program (NPP).

MitoGENE helps patients obtain Uplizna (inebilizumab-cdon) legally and safely, in collaboration with their treating doctor. We assist with documentation, import coordination, and delivery—ensuring full compliance with Indian regulatory guidelines.

If you or a loved one needs Uplizna (inebilizumab-cdon), MitoGENE is here to guide you through every step of the process.

---

Disease Indications:Neuromyelitis Optica Spectrum Disorder

Manufacturer:Viela Bio

Usage:Intravenous

Medicine Approved by:

• U.S. Food and Drug Administration (FDA)

---

Available Dosage Form & Package:

• 3 Single dose vials 100mg/10ml

Shipping:Cold Chain Shipping. Certain medicines can be affected by heat, light, or improper handling. Cold chain shipping uses temperature-controlled packaging and transport provided by specialized medical couriers to keep these medicines stable and effective. Due to the added care and equipment involved, this method is often more expensive than standard shipping.